BSH SIG podcasts – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

BSH SIG podcasts

British Society for Haematology

Health & Fitness

Frequency: 1 episode/10d. Total Eps: 13

BSH Specialist Interest Group Podcasts

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇬🇧 Great Britain - medicine
08/08/2026
#86
🇬🇧 Great Britain - medicine
05/07/2026
#75
🇬🇧 Great Britain - medicine
03/07/2026
#76
🇬🇧 Great Britain - medicine
07/06/2025
#100
🇬🇧 Great Britain - medicine
02/06/2025
#85

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 42%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Lymphoma SIG Podcast Episode 15

Episode 14

Friday, July 11, 2025 • Duration 23:27

Lymphoma Sig Podcast Episode 14 Mantle cell lymphoma – first-line treatment in 2025 – by Dr David Lewis

Episode 13

Friday, July 4, 2025 • Duration 42:19

This podcast is the first of a series of three recordings of the Lymphoma Special Interest Group (SIG) Education Session at the 2025 BSH Annual Scientific Meeting. The Lymphoma SIG is delighted to share talks from three great speakers with the wider audience.

In this recording, Dr David Lewis discusses first-line treatment for mantle cell lymphoma in 2025, focusing on three main themes: 1) the emerging use of Bruton’s tyrosine kinase inhibitors (BTKis) in first-line treatment, 2) the role of autologous stem cell transplant, and 3) the clinical utility of minimal residual disease (MRD).

Dr David Lewis is a Consultant Haematologist at the University Hospitals Plymouth and an Honorary Associate Professor at the University of Plymouth. He is the Chief Investigator of the ENRICH trial – a randomised, open-label study of Rituximab/Ibrutinib versus. Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma.

Read moreCollapse

Lymphoma SIG Podcast 3 - Management of Waldenström macroglobulinaemia

Episode 3

Tuesday, March 11, 2025 • Duration 30:01

Dr Shirley D’Sa discusses the management of Waldenström macroglobulinaemia (WM).

Dr D’Sa is a haematologist and associate professor at University College London Hospitals NHS Foundation Trust (UCLH), a busy academic centre in central London, where she also completed her specialist training in haematology.

She specialises in the management of patients with Immunoglobulin M (IgM) related conditions and paraproteinaemic neuropathies.

She is the clinical lead for the UCLH Centre for WM and Related Disorders and haematological lead in the Joint Neurohaematology Service alongside the neurology lead, Professor Michael Lunn, at the National Hospital for Neurology, Queen Square, London.

Dr D’Sa is a co-trustee with patients and colleagues in the UK-registered charity, WMUK. She is the Chief Investigator for the Rory Morrison Registry project for WM and associated conditions, which has more than 1,200 patients registered from several centres across the UK. And a member of the UK Medical Advisory Panel of Lymphoma Action.

Dr D’Sa is a CI/PI in several clinical trials in WM and cold agglutinin disease (CAD) and is a committee member of the International Workshops on WM and the BSH Guidelines group.

She is a supervisor to successive research fellows in the field of Waldenström and paraproteinaemic neuropathies, as well as haematology specialist trainees and undergraduates at the University College London (UCL) Medical School.

Read moreCollapse

Lymphoma SIG Podcast 2 - Clinical management of mantle cell lymphoma

Episode 2

Tuesday, March 11, 2025 • Duration 30:11

Dr Rory McCulloch discusses the clinical management of mantle cell lymphoma (MCL), including indolent MCL, upfront management in younger patients, challenges of aggressive blastoid disease and how new therapies may shape future treatment algorithms.

Dr McCulloch is a consultant haematologist at Gloucestershire Hospitals NHS Foundation Trust and recently worked as a Lymphoma Clinical Research Fellow under Professor Simon Rule at Plymouth University.

He was vice-chair of the trainee-led research network HaemSTAR and is a BSH Lymphoma Special Interest Group member.

Read moreCollapse

Lymphoma SIG Podcast 1 - Management of patients with early, unfavourable Hodgkin's lymphoma

Episode 1

Tuesday, March 11, 2025 • Duration 22:30

Dr Wendy Osborne discusses an approach to the management of patients with early, unfavourable Hodgkin's lymphoma, focusing on the current evidence, the role of positron emission tomography (PET) and the challenges faced by this subgroup of patients.

Dr Osborne is a consultant haematologist at Newcastle upon Tyne Hospitals NHS Foundation Trust. She has a specialist interest in the field of lymphoma, is a member of the National Cancer Research Institute (NCRI) clinical subgroups looking at high-grade Hodgkin's and T cell lymphomas, and is the chair of the BSH Lymphoma Special Interest Group.

Read moreCollapse

Lymphoma SIG Podcast 13 – BSH 2025 Highlights – Top Abstracts in Lymphoma with Dr Cathy Burton

Episode 12

Friday, June 27, 2025 • Duration 13:32

Dr Cathy Burton chaired the “Top Abstracts in Lymphoma” session at BSH 2025. In this episode, she shares with us the highlights from this session.

Dr Burton is a Consultant Haematologist at St James’s University Hospital, Leeds, specializing in Lymphoma and Diagnostics. She is heavily engaged in translational research in lymphoma and is Chair of the Hodgkin lymphoma study group, Deputy Chair of the Lymphoma Science study group and a member of the UK Lymphoma Research Group. She has recently been involved in writing the diffuse large B cell lymphoma guidelines and is the chair of the BSH Lymphoma Special Interest Group.

Read moreCollapse

Lymphoma SIG Podcast 11 - BSH 2025 Highlights - Dr Sridhar Chaganti updates regarding large B cell lymphoma

Episode 10

Friday, June 6, 2025 • Duration 17:48

In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment.

Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy. He is the chair of the high-grade lymphoma study group and co-chairs the national CAR-T panel.

Read moreCollapse

Lymphoma SIG Podcast 10 - BSH 2025 Highlights in Hodgkin Lymphoma with Professor Graham Collins

Episode 9

Friday, May 23, 2025 • Duration 11:57

In this episode, Professor Graham Collins shares with us the highlights in Hodgkin lymphoma from BSH 2025. He takes us through the ECHELON-1 trial, which led to the recent NICE approval of Brentuximab-AVD as a frontline treatment option for advanced stage Hodgkin lymphoma.

Read moreCollapse

Lymphoma SIG Podcast episode 9 - Primary Mediastinal B-Cell Lymphoma

Episode 8

Friday, May 16, 2025 • Duration 19:32

Professor Graham Collins discusses the management of primary mediastinal B-cell lymphoma, from initial treatment considerations to the management of relapsed disease.

Professor Collins is a Consultant Haematologist and the lymphoma lead clinician at the Oxford Cancer and Haematology Centre. He has particular interests in Hodgkin and high-grade non-Hodgkin lymphoma and he chairs the national CAR-T panel for lymphoma.

Please note that since the recording of this podcast in December 2024, NICE has granted approval for the use of Liso-cel as a second-line treatment option in primary mediastinal B-cell lymphoma.

Read moreCollapse

Lymphoma SIG Podcast 8 - Bispecific T-cells engagers in Lymphoma

Episode 7

Friday, May 9, 2025 • Duration 31:26

Dr Sridhar Chaganti discusses the use of bispecific T-cell engagers (BITE’s) in large B-cell lymphoma.

Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham.

His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematological malignancies, lymphomas, stem cell transplantation and cellular therapies.

Read moreCollapse

BSH SIG podcasts – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

BSH SIG podcasts – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other3

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Other3

Related Shows Based on Content Similarities